CD40LG and myeloid sarcoma: More recent studies have focused as well on aPL autoantibodies incidence in MS patients in different clinical phases of the disease, showing at least one IgM aPL or IgG isotype elevated in MS subjects, in RRMS or SPMS phases (Mandoj et al., 2015; Shor et al., 2015; Filippidou et al., 2016).